GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
| 
                                                                Synonyms: BMS-224818 | LEA29Y | Nulojix®
                                 belatacept is an approved drug (FDA (2011), EMA (2011)) Compound class: 
                                                            Peptide
                                 
                                    
                                        Comment: A recombinant protein fusing the extracellular domain of human cytotoxic T-lymphocyte-associated antigen 4 (CTLA-4) to the modified Fc (hinge, CH2, and CH3 domains) portion of human immunoglobulin G1 (IgG1). CTLA-4 is essential for T-cell co-activation. Belatecept differs from abatacept by only 2 amino acids.   View more information in the IUPHAR Pharmacology Education Project: belatacept | 
| Bioactivity Comments | 
| Belatacept binds to human CD86 with an IC50 of 0.102µg/mL and to CD80 with an IC50 of 0.009µg/mL [1]. | 
| Selectivity at other protein targets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 
 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||